## REPORT DOCUMENTATION PAGE

Unclassified

Form Approved

OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND D	ATES COVERED	
•	15 January 1999	Final l Octobe	er 1997-30 S	eptember 1998
4. TITLE AND SUBTITLE			5. FUNDING NUMBE	
Children's Hospital of			N00014-97-1	-1060
Molecular Typing of All		and Class II		
Loci on Blood Spotted	Filter Paper			
6. AUTHOR(S)				
Massimo Trucco, M.D.				
				,
7. PERFORMING ORGANIZATION NAME	C/C) AND ADDESC/ES)		8. PERFORMING OR	GANIZATION
			REPORT NUMBER	
Children's Hospital of Rangos Research Center	-		335	
3460 Fifth Avenue	51			
Pittsburgh, PA 15213	3-3205			
Treesburgh, In 1321	3 32 03			
9. SPONSORING / MONITORING AGENC	Y NAMES(S) AND ADDRESS(ES)		10. SPONSORING/	
Department of the Nav	vy		AGENCY REPOR	RT NUMBER
Office of Naval Resea	arch	1		
800 North Quincy Str				
Arlington, VA 22217	-5660	4.0	99012	በ 1በፍ
11. SUPPLEMENTARY NOTES		Y	44U I C	כטו ט
		1.7	, , <del>u</del> . =	• . • •
a. DISTRIBUTION / AVAILABILITY STATE	EMENT		12. DISTRIBUTION (	CODE
Approved for Public	Release; distribution	is Unlimited.	•.	
		•		
13. ABSTRACT (Maximum 200 words)				
	man's Userital of Dittshurgh	Histogompatibility (	Contar oon ba	lossified under
three major categories: 1	ren's Hospital of Pittsburgh) the repository service; 2)	the molecular typin	a service, and	3) the recearch
activities aimed at improv	ving the technical support	on which the previo	g scivice, and	s are working
	y, where blood samples from			
from more than 120 recrui	iting centers nationwide, ro	ughly 150,000 samr	oles were proce	ssed. Close to
	l in three sets of freezers (c			
130,000 were sent out to	o other Typing Laboratori	ies. In our laborat	ories, approxi	mately 10,000
typings were performed	with a very high Q.C. star	dard, as monitored	by National I	Marrow Donor
	search branch synthesized a			
or labelled probes to per-	form molecular HLA typir	ng. DNA sequencia	ng was also pe	erformed when
hybridization results were	e not optimal. Alternatives	s for storing blood	samples (e.g.,	blood spots on
filter paper) or for enha	incing typing capabilities	(e.g., microchip to	echnology to	expedite PCR
	ssfully implemented or in	nproved to the poi	nt of justifyir	ng their future
implementation.				
AA CUD IECT TEDIS			15. NU	MBER OF PAGES
14. SUBJECT TERMS			1.5. 1.6.	7
			16. PRI	CE CODE
17. SECURITY CLASSIFICATION	18. SECURITY CLASSIFICATION	19. SECURITY CLASSIFICA	ATION 20. LIM	ITATION OF ABSTRACT
OF REPORT	OF THIS PAGE	OF ABSTRACT		

UL Standard Form 298 (Rev. 2-89) Prescribed by ANISE Sad 239-16 296-102

Unclassified

Unclassified

## CHILDREN'S HOSPITAL OF PITTSBURGH HISTOCOMPATIBILITY CENTER

AWARD NUMBER: N00014-97-1-1060

Total Samples Typed and Results Sent from 10/01/97 to 09/30/98

	Total	Priority 1	Priority 2	Priority 3	No Makes	Navy
1997						
October	1013	119	894	0	0	0
November	851	161	690	0	0	0
December	822	122	700	0	3	0
1998						
January	838	130	708	0	Ö	0
February	854	263	591	0	1	0
March	1029	348	681	0	2	0
April	820	174	646	0	0	0
May	976	116	860	0	0	0
June	865	300	565	0	0	0
July	805	49	756	0	0	0
August	818	159	659	0	0	0
September	1026	188	838	0	0	0

## CHILDREN'S HOSPITAL OF PITTSBURGH HISTOCOMPATIBILITY CENTER

AWARD NUMBER: N00014-97-1-1060

Total Samples Received, Stored and Shipped from the Repository from 10/01/97 to 09/30/98

SAMPLES	NUMBER	NUMBER	NUMBER
	(October1997)	(November 1997)	(December 1997)
Stored	11,593	13,743	12,523
Shipped (AB - Class I)	4,700	5,800	7,400
Shipped (DR - Class II)	9,394	6,614	8,463
Not stored	87	113	149
Destroyed	0	238	0
1	# · · ·		•
SAMPLES	NUMBER	NUMBER	NUMBER
	(January '98)	(February '98)	(March '98)
	(0		
Stored	8,192	7,437	16,264
Stored Shipped (AB - Class I)		7,437 4,300	16,264 5,100
	8,192		
Shipped (AB - Class I)	8,192 3,400	4,300	5,100

SAMPLES	NUMBER	NUMBER	NUMBER
	(April '98)	(May '98)	(June '98)
Stored	14,769	14,028	11,628
Shipped (AB - Class I)	5,250	4,100	5,700
Shipped (DR - Class II)	4,862	4,580	4,140
Not stored	173	99	98
Destroyed	464	0	1,131
		1	
SAMPLES	NUMBER	NUMBER	NUMBER
	(July '98)	(August '98)	(September '98)
Stored	11,709	10,703	10,601
Shipped (AB - Class I)	5,100	4,300	3,175
Shipped (DR - Class II)	4,031	4,668	5,115
Not stored	101	143	59
Destroyed 1,594		588	2,039

- <u>Stored samples</u> (Multiply number stored x 3 because of triplicate aliquots)
- <u>Shipped samples</u> (Separated by AB and DR samples)
- <u>Not Stored</u> because of insufficient quantity; duplicate tubes; too clotted; broken; wrong anti-coagulant.
- <u>Destroyed</u> because no longer eligible, so that blood sample must be removed from NMDP list.

## CHILDREN'S HOSPITAL OF PITTSBURGH HISTOCOMPATIBILITY CENTER

AWARD NUMBER: N00014-97-1-1060

Research Completed from 10/01/97 to 09/30/98

Month/ Year:	Oligonucleotides Synthesized:	ABI/PE Sequencing:	Visible Genetics Sequencing:	Research Projects:
Oct '97	31	163 reactions	0*	Began exploring optimal PCR conditions for both HLA-A and HLA-B typing using Visible Genetics Microblaster Sequencer.  Continued to expand cell reference lines for cell and DNA bank.  Synthesized 1 Taqman Probe.
Nov '97	26	42 reactions	0*	New Rhodamine terminator chemistry validated on sequencer.  Rhodamine matrix installed on sequencer.  Installation of Visible Genetics Sequencer.  Class 1 HLA-A and HLA-B PCR amplification optimized for sequencing conditions.
Dec '97	16	104	14	Performed control samples for Class 1 typing on Visible Genetics sequencer.  Continued to optimize amplifications and cycle sequencing for HLA-A and HLA-B.
Jan '98	24	94	5	Began training personnel on Visible Genetics Sequencer for Class 1 typing.  Performed a quality control study for Visible Genetics sequencer using 3 unknown typing samples and 3 known typing samples.

Month/ Year:	Oligonucleotides Synthesized:	ABI/PE Sequencing:	Visible Genetics Sequencing:	Research Projects:
Feb '98	62	65	11	Set up data base for Visible Genetics Class 1 typing.
				Continued validation of Class 1 typing via sequencing.
				Troubleshooting on Class 1 typing reactions using Visible Genetics sequencer.
Mar '98	31	130	7	Big Dye terminator chemistry validated and installed on sequencer.
				Optimized cycle sequencing for Big Dye Terminator Kit.
				Expanded cell line references.
				Continued troubleshooting on Class 1 typing reactions using Visible Genetics sequencer.
Apr '98	26	88	2	Continued to optimized cycle sequencing for Big Dye Terminator Kit.
				Evaluated and optimized PCR "clean up" methods for new sequencing chemistry.
				Continued to expanded cell line references.
May '98	19	117	3	Installed and updated Visible Genetics sequencer: OpenStep 3.0 software.
1				Synthesized 3 Taqman Probes.
				Began evaluating DNA sequencing systems using capillary electrophoresion a computer chip.
				Continued to expanded cell line references.

Month/ Year:	Oligonucleotides Synthesized:	ABI/PE Sequencing:	Visible Genetics Sequencing:	Research Projects:
Jun '98	43	89	11	Evaluated sequencing methods for chip technology.
				Developed chip design for DNA sequencing.
				Initiated orders for chip sequencing.
				Installed Iomega "Jazz" System tape back-up for the hard drive on the Visible Genetics Sequencer.
				Synthesized 1 Taqman Probe.
				Continued to expanded cell line references.
Month/ Year:	Oligonucleotides Synthesized:	ABI/PE Sequencing:	CE Sequencing**:	Research Projects:
July '98	41	124	12	Began instrumental set-up for DNA sequencing via capillary electrophoresis (CE) - computer chip technology.
				Optimized PCR for CE sequencing
Aug '98	28	86	18	Explored polymers and began initial testing.
				Continued instrumental set-up for CE chip sequencing runs.
				Continued optimizing PCR conditions for CE runs.
Sep '98	22	125	10	Continued optimizing PCR conditions for CE runs.
				Continued to evaluate polymers for CE sequencing.
				Began literature search on new HPLC techniques for DNA purification.

<sup>\*</sup> Visible Genetics sequencing instrument was not yet purchased at this time.

<sup>\*\*</sup> Instituted new project utilizing capillary electrophoresis (CE) for DNA sequencing in July 1998.